Walleye Capital
NVO

Walleye Capital’s Novo Nordisk NVO Stock Holding History

Walleye Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.31M Sell
194,159
-384,150
-66% -$16.5M 0.03% 510
2026
Q1 		$21.3M Buy
578,309
+77,665
+16% +$3.68M 0.09% 174
2025
Q4 		$25.5M Buy
500,644
+356,879
+248% +$18.2M 0.08% 211
2025
Q3 		$7.98M Buy
143,765
+143,737
+513,346% +$8.41M 0.03% 646
2025
Q2 		$1.93K Sell
28
-190,926
-100% -$13M ﹤0.01% 4388
2025
Q1 		$13.3M Buy
190,954
+28,867
+18% +$2.38M 0.06% 320
2024
Q4 		$13.9M Sell
162,087
-89,839
-36% -$9.72M 0.03% 459
2024
Q3 		$30M Buy
251,926
+69,241
+38% +$9.23M 0.06% 217
2024
Q2 		$26.1M Buy
182,685
+78,134
+75% +$10.4M 0.05% 268
2024
Q1 		$13.4M Sell
104,551
-34,065
-25% -$4.06M 0.02% 646
2023
Q4 		$14.3M Sell
138,616
-54,179
-28% -$5.36M 0.03% 499
2023
Q3 		$17.5M Buy
+192,795
New +$17M 0.04% 307

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Walleye Capital's NVO Position: Q2 2026 in Review

Walleye Capital reduced its Novo Nordisk (NVO) stake by 66% in Q2 2026, selling an estimated $16.5M and leaving 194,159 shares worth $9.31M. The position accounts for 0.03% of the portfolio, ranked #510.

Walleye Capital first reported a position in NVO in Q3 2023 and has held it in 12 quarters since. The position peaked at $30M in Q3 2024. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Walleye Capital held 194,159 shares of Novo Nordisk worth $9.31M as of Q2 2026.
  • Walleye Capital sold 384,150 Novo Nordisk shares in Q2 2026, an estimated $16.5M.
  • Novo Nordisk made up 0.03% of Walleye Capital's portfolio in Q2 2026, its #510 holding.
  • Walleye Capital first reported a position in Novo Nordisk in Q3 2023 and has held it in 12 quarters since.
  • Walleye Capital's Novo Nordisk position peaked at $30M in Q3 2024.
  • 1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.